Nephrogenic Systemic Fibrosis and Gadolinium-Based Contrast Agents

Advances in Chronic Kidney Disease

Volumn 18, Issue 3, 2011, Pages 188-198

  Abu Alfa, Ali K ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Gadolinium; Kidney diseases; Magnetic resonance imaging; Nephrogenic systemic fibrosis; Policy

Indexed keywords

ABLAVAR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CONTRAST MEDIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ECHOVIST; GADAVIST; GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOFOSVESET; GADOLINIUM; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; GADOXETIC ACID; IMATINIB; RAPAMYCIN; SODIUM THIOSULFATE; TAMOXIFEN; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ATTRIBUTABLE RISK; CHRONIC KIDNEY DISEASE; CLINICAL FEATURE; DISEASE ASSOCIATION; FOOD AND DRUG ADMINISTRATION; HEMODIALYSIS; HUMAN; KIDNEY DISEASE; KIDNEY FAILURE; MORBIDITY; MORTALITY; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; PATIENT ASSESSMENT; PATIENT CARE; PERITONEAL DIALYSIS; PRIORITY JOURNAL; PUVA; REVIEW; RISK BENEFIT ANALYSIS; RISK REDUCTION;

CONTRAST MEDIA; GADOLINIUM; HUMANS; KIDNEY DISEASES; MAGNETIC RESONANCE IMAGING; NEPHROGENIC FIBROSING DERMOPATHY; RISK FACTORS;

EID: 79955395894     PISSN: 15485595     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.ackd.2011.03.001     Document Type: Review

References (129)

1. Cowper S.E., Robin H.S., Steinberg S.M., et al. Scleromyxedema-like cutaneous diseases in renal-dialysis patients. Lancet 2000, 356:1000-1001.
2. Cowper S.E., Su L.D., Bhawan J., Robin H.S., LeBoit P.E. Nephrogenic fibrosing dermopathy. Am J Dermatopathol 2001, 23:383-393.
3. Jimenez S.A., Artlett C.M., Sandorfi N., et al. Dialysis-associated systemic fibrosis (nephrogenic fibrosing dermopathy): study of inflammatory cells and transforming growth factor beta1 expression in affected skin. Arthritis Rheum 2004, 50:2660-2666.
4. Abu-Alfa A. The impact of NSF on the care of patients with kidney disease. J Am Coll Radiol 2008, 5:45-52.
5. Ting W.W., Stone M.S., Madison K.C., Kurtz K. Nephrogenic fibrosing dermopathy with systemic involvement. Arch Dermatol 2003, 139:903-906.
6. Kucher C., Steere J., Elenitsas R., Siegel D.L., Xu X. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis with diaphragmatic involvement in a patient with respiratory failure. J Am Acad Dermatol 2006, 54(2 suppl):S31-S34.
7. Cowper S.E. Nephrogenic systemic fibrosis: the nosological and conceptual evolution of nephrogenic fibrosing dermopathy. Am J Kidney Dis 2005, 46:763-765.
8. Krous H., Breisch E., Chadwick A., et al. Nephrogenic systemic fibrosis with multiorgan involvement in a teenage male after lymphoma, Ewing sarcoma, end stage renal disease, and hemodialysis. Pediatr Dev Pathol 2007, 10:395-402.
9. Ledneva E., Karie S., Launay-Vacher V., Janus N., Deray G. Renal safety of gadolinium-based contrast media in patients with chronic renal insufficiency. Radiology 2009, 250:618-628.
10. Marckmann P. An epidemic outbreak of nephrogenic systemic fibrosis in a Danish hospital. Eur J Radiol 2008, 66:187-190.
11. Barrantes F., Carlson K., Girardi M., Cowper S.E., Abu-Alfa A.K. Post-Exposure Inflammatory State and Late Presentation of NSF: a New Concern for Exposed Patients? Poster presented at the Third Annual Scientific Symposium on NSF and GBCA May 9, 2008, Yale University, New Haven, CT.
12. Grebe S.O., Borrmann M., Altenburg A., et al. Chronic inflammation and accelerated atherosclerosis as important cofactors in nephrogenic systemic fibrosis following intravenous gadolinium exposure. Clin Exp Nephrol 2008, 12:403-406.
13. Broome D.R., Girguis M.S., Baron P.W., et al. Gadodiamide-associated nephrogenic systemic fibrosis: why radiologists should be concerned. Am J Roentgenol 2007, 188:586-592.
14. Cowper S.E. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 2003, 15:785-790.
15. Cowper S.E. Nephrogenic systemic fibrosis: a review and exploration of the role of gadolinium. Adv Dermatol 2007, 23:131-154.
16. DeHoratius D.M., Cowper S.E. Nephrogenic systemic fibrosis: an emerging threat among renal patients. Semin Dial 2006, 19:191-194.
17. Streams B.N., Liu V., Liegeois N., Moschella S.M. Clinical and pathologic features of nephrogenic fibrosing dermopathy: a report of two cases. J Am Acad Dermatol 2003, 48:42-47.
18. Kay J., Bazari H., Avery L.L., Koreishi A.F. Case records of the Massachusetts General Hospital. Case 6-2008. A 46-year-old woman with renal failure and stiffness of the joints and skin. N Engl J Med 2008, 358:827-838.
19. Girardi MD, Kay J, Elston DM, et al. Nephrogenic systemic fibrosis: clinicopathological definition and work-up recommendations. J Am Acad Dermatol. In press.
20. High W.A., Ayers R.A., Chandler J., Zito G., Cowper S.E. Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2007, 56:21-26.
21. Weiss A.S., Lucia M.S., Teitelbaum I. A case of nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis. Nat Clin Pract Nephrol 2007, 3:111-115.
22. Boyd A.S., Sanyal S., Abraham J.L. Gadolinium is not deposited in the skin of patients with normal renal function after exposure to gadolinium-based contrast agents. J Am Acad Dermatol 2008, 59:356-358.
23. Cowper S.E., Bucala R., Leboit P.E. Nephrogenic fibrosing dermopathy/nephrogenic systemic fibrosis-setting the record straight. Semin Arthritis Rheum 2006, 35:208-210.
24. Grobner T. Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis?. Nephrol Dial Transplant 2006, 21:1104-1108.
25. Collidge T.A., Thomson P.C., Mark P.B., et al. Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: retrospective study of a renal replacement therapy cohort. Radiology 2007, 245:168-175.
26. Deo A., Fogel M., Cowper S.E. Nephrogenic systemic fibrosis: a population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2007, 2:264-267.
27. Othersen J.B., Maize J.C., Woolson R.F., Budisavljevic M.N. Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant 2007, 22:3179-3185.
28. Marckmann P., Skov L., Rossen K., Heaf J.G., Thomsen H.S. Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007, 22:3174-3178.
29. Shabana W.M., Cohan R.H., Ellis J.H., et al. Nephrogenic systemic fibrosis: a report of 29 cases. Am J Roentgenol 2008, 190:736-741.
30. Khurana A., Greene J.F., High W.A. Quantification of gadolinium in nephrogenic systemic fibrosis: re-examination of a reported cohort with analysis of clinical factors. J Am Acad Dermatol 2008, 59:218-224.
31. Thakral C., Abraham J.L. Nephrogenic systemic fibrosis: histology and gadolinium detection. Radiol Clin North Am 2009, 47:841-853. vi-vii.
32. Christensen K.N., Lee C.U., Hanley M.M., et al. Quantification of gadolinium in fresh skin and serum samples from patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 2011, 64:91-96.
33. Abraham J.L., Thakral C., Skov L., Rossen K., Marckmann P. Dermal inorganic gadolinium concentrations: evidence for in vivo transmetallation and long-term persistence in nephrogenic systemic fibrosis. Br J Dermatol 2008, 158:273-280.
34. High W.A., Ranville J.F., Brown M., et al. Gadolinium deposition in nephrogenic systemic fibrosis: an examination of tissue using synchrotron x-ray fluorescence spectroscopy. J Am Acad Dermatol 2010, 62:38-44.
35. Perez-Rodriguez J., Lai S., Ehst B.D., Fine D.M., Bluemke D.A. Nephrogenic systemic fibrosis: incidence, associations, and effect of risk factor assessment-report of 33 cases. Radiology 2009, 250:371-377.
36. Prince M.R., Zhang H., Morris M., et al. Incidence of nephrogenic systemic fibrosis at two large medical centers. Radiology 2008, 248:807-816.
37. Wahba I.M., Simpson E.L., White K. Gadolinium is not the only trigger for nephrogenic systemic fibrosis: insights from two cases and review of the recent literature. Am J Transplant 2007, 7:2425-2432.
38. Hedley A.J., Molan M.P., Hare D.L., Anavekar N.S., Ierino F.L. Nephrogenic systemic fibrosis associated with gadolinium-containing contrast media administration in patients with reduced glomerular filtration rate. Australas Radiol 2007, 51:300.
39. Song J., Volkov S., Shea C.R., et al. Nephrogenic systemic fibrosis associated with stromal and vascular calcification, report of two cases. J Cutan Pathol 2009, 1(36 suppl):31-34.
40. Lemy A.A., del Marmol V., Kolivras A., et al. Revisiting nephrogenic systemic fibrosis in 6 kidney transplant recipients: a single-center experience. J Am Acad Dermatol 2010, 63:389-399.
41. Morcos S.K. Experimental studies investigating the pathophysiology of nephrogenic systemic fibrosis; what did we learn so far?. Eur Radiol 2011, 21:496-500.
42. Sieber M.A., Steger-Hartmann T., Lengsfeld P., Pietsch H. Gadolinium-based contrast agents and NSF: evidence from animal experience. J Magn Reson Imaging 2009, 30:1268-1276.
43. Hope T.A., High W.A., Leboit P.E., et al. Nephrogenic systemic fibrosis in rats treated with erythropoietin and intravenous iron. Radiology 2009, 253:390-398.
44. Frenzel T., Lengsfeld P., Schirmer H., Hutter J., Weinmann H.J. Stability of gadolinium-based magnetic resonance imaging contrast agents in human serum at 37 degrees C. Invest Radiol 2008, 43:817-828.
45. Broome D.R. Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: a summary of the medical literature reporting. Eur J Radiol 2008, 66:230-234.
46. Wertman R., Altun E., Martin D.R., et al. Risk of nephrogenic systemic fibrosis: evaluation of gadolinium chelate contrast agents at four American universities. Radiology 2008, 248:799-806.
47. Reilly R.F. Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. Clin J Am Soc Nephrol 2008, 3:747-751.
48. Wollanka H., Weidenmaier W., Giersig C. NSF after Gadovist exposure: a case report and hypothesis of NSF development. Nephrol Dial Transplant 2009, 24:3882-3884.
49. Collidge T., Thomson P., Mark P., Willinek W., Roditi G. Is this really a true case of NSF following Gadovist exposure alone?. Nephrol Dial Transplant 2010, 25:1352-1353. author reply 1353-1354.
50. Martin D.R., Krishnamoorthy S.K., Kalb B., et al. Decreased incidence of NSF in patients on dialysis after changing gadolinium contrast-enhanced MRI protocols. J Magn Reson Imaging 2010, 31:440-446.
51. Altun E., Martin D.R., Wertman R., et al. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy-report from two U.S. universities. Radiology 2009, 253:689-696.
52. European Medicines Agency (EMEA). Gadolinium-containing MRI contrast agents and Nephrogenic Systemic Fibrosis (NSF); February 7, 2007. Available at: Accessed December 26, 2008. http://www.ismrm.org/special/EMEA1.pdf.
53. European Medicines Agency (EMEA). European Medicines Agency makes recommendations to minimize risk of nephrogenic systemic fibrosis with gadolinium-containing contrast agents; November 20, 2009. Available at: Accessed December 23, 2010. http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2009/11/WC500015569.pdf.
54. Food and Drug Administration. FDA: new warnings required on use of gadolinium-based contrast agents. Enhanced screening recommended to detect kidney dysfunction. Septemeber 9, 2010. Available at: Accessed December 26, 2010. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm225286.htm.
55. Food and Drug Administration. FDA Drug Safety Communication: new warnings for using gadolinium-based contrast agents in patients with kidney dysfunction; December 20, 2010. Available at: Accessed December 26, 2010. http://www.fda.gov/Drugs/DrugSafety/ucm223966.htm.
56. McLachlan S.J., Eaton S., De Simone D.N. Pharmacokinetic behavior of gadoteridol injection. Invest Radiol 1992, 27(suppl 1):S12-S15.
57. Yoshikawa K., Davies A. Safety of ProHance in special populations. Eur Radiol 1997, 7(suppl 5):246-250.
58. Swan S.K., Lambrecht L.J., Townsend R., et al. Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. Invest Radiol 1999, 34:443-448.
59. Bracco. MultiHance Package Insert. Available at: Accessed December 26, 2010. http://www.multihanceusa.com/pages/productINFO.htm#.
60. Joffe P., Thomsen H.S., Meusel M. Pharmacokinetics of gadodiamide injection in patients with severe renal insufficiency and patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Acad Radiol 1998, 5:491-502.
61. Berg K.J., Lundby B., Reinton V., Nordal K.P., Rootwelt K., Smith H.J. Gadodiamide in renal transplant patients: effects on renal function and usefulness as a glomerular filtration rate marker. Nephron 1996, 72:212-217.
62. Swan S.K., Baker J.F., Free R., et al. Pharmacokinetics, safety, and tolerability of gadoversetamide injection (OptiMARK) in subjects with central nervous system or liver pathology and varying degrees of renal function. J Magn Reson Imaging 1999, 9:317-321.
63. Schuhmann-Giampieri G., Krestin G. Pharmacokinetics of Gd-DTPA in patients with chronic renal failure. Invest Radiol 1991, 26:975-979.
64. Lantheus Medical Imaging. Ablavar package insert. Available at: Accessed December 26, 2010. http://www.ablavar.com/prescribing.html.
65. Bayer Healthcare Pharmaceuticals. Eovist Package Insert. Available at: Accessed December 26, 2010. http://www.berlex.com/html/products/pi/Eovist_PI.pdf.
66. Marckmann P., Skov L., Rossen K., et al. Nephrogenic systemic fibrosis: suspected causative role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 2006, 17:2359-2362.
67. Lauenstein T.C., Salman K., Morreira R., et al. Nephrogenic systemic fibrosis: center case review. J Magn Reson Imaging 2007, 26:1198-1203.
68. Rydahl C., Thomsen H.S., Marckmann P. High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 2008, 43:141-144.
69. Todd D.J., Kagan A., Chibnik L.B., Kay J. Cutaneous changes of nephrogenic systemic fibrosis: predictor of early mortality and association with gadolinium exposure. Arthritis Rheum 2007, 56:3433-3441.
70. Sadowski E.A., Bennett L.K., Chan M.R., et al. Nephrogenic systemic fibrosis: risk factors and incidence estimation. Radiology 2007, 243:148-157.
71. Lee C.U., Wood C.M., Hesley G.K., et al. Large sample of nephrogenic systemic fibrosis cases from a single institution. Arch Dermatol 2009, 145:1095-1102.
72. Wiginton C.D., Kelly B., Oto A., et al. Gadolinium-based contrast exposure, nephrogenic systemic fibrosis, and gadolinium detection in tissue. Am J Roentgenol 2008, 190:1060-1068.
73. Khurram M., Skov L., Rossen K., Thomsen H.S., Marckmann P. Nephrogenic systemic fibrosis: a serious iatrogenic disease of renal failure patients. Scand J Urol Nephrol 2007, 41:565-566.
74. Swartz R.D., Crofford L.J., Phan S.H., Ike R.W., Su L.D. Nephrogenic fibrosing dermopathy: a novel cutaneous fibrosing disorder in patients with renal failure. Am J Med 2003, 114:563-572.
75. Mackay-Wiggan J.M., Cohen D.J., Hardy M.A., Knobler E.H., Grossman M.E. Nephrogenic fibrosing dermopathy (scleromyxedema-like illness of renal disease). J Am Acad Dermatol 2003, 48:55-60.
76. Khurana A., Runge V.M., Narayanan M., Greene J.F., Nickel A.E. Nephrogenic systemic fibrosis: a review of 6 cases temporally related to gadodiamide injection (omniscan). Invest Radiol 2007, 42:139-145.
77. Maloo M., Abt P., Kashyap R., et al. Nephrogenic systemic fibrosis among liver transplant recipients: a single institution experience and topic update. Am J Transplant 2006, 6:2212-2217.
78. Baron P.W., Cantos K., Hillebrand D.J., et al. Nephrogenic fibrosing dermopathy after liver transplantation successfully treated with plasmapheresis. Am J Dermatopathol 2003, 25:204-209.
79. Jan F., Segal J.M., Dyer J., et al. Nephrogenic fibrosing dermopathy: two pediatric cases. J Pediatr 2003, 143:678-681.
80. Panesar M., Banerjee S., Barone G.W. Clinical improvement of nephrogenic systemic fibrosis after kidney transplantation. Clin Transplant 2008, 22:803-808.
81. Cuffy MC, Singh M, Formica R, et al. Renal transplantation for nephrogenic systemic fibrosis: a case report and review of the literature. Nephrol Dial Transplant. In press.
82. Leung N., Shaikh A., Cosio F.G., et al. The outcome of patients with nephrogenic systemic fibrosis after successful kidney transplantation. Am J Transplant 2010, 10:558-562.
83. Gilliet M., Cozzio A., Burg G., Nestle F.O. Successful treatment of three cases of nephrogenic fibrosing dermopathy with extracorporeal photopheresis. Br J Dermatol 2005, 152:531-536.
84. Wahba I.M., White K., Meyer M., Simpson E.L. The case for ultraviolet light therapy in nephrogenic fibrosing dermopathy-report of two cases and review of the literature. Nephrol Dial Transplant 2007, 22:631-636.
85. Richmond H., Zwerner J., Kim Y., Fiorentino D. Nephrogenic systemic fibrosis: relationship to gadolinium and response to photopheresis. Arch Dermatol 2007, 143:1025-1030.
86. Yerram P., Saab S., Karuparthi P., Hayden M., Khanna R. Nephrogenic systemic fibrosis: a mysterious disease in patients with renal failure-role of gadolinium-based contrast media in causation and the beneficial effect of intravenous sodium thiosulfate. Clin J Am Soc Nephrol 2007, 2:258-263.
87. Kadiyala D., Roer D.A., Perazella M.A. Nephrogenic systemic fibrosis associated with gadoversetamide exposure: treatment with sodium thiosulfate. Am J Kidney Dis 2009, 53:133-137.
88. Kay J., High W.A. Imatinib mesylate treatment of nephrogenic systemic fibrosis. Arthritis Rheum 2008, 58:2543-2548.
89. Davison R., Mead P. Nephrogenic systemic fibrosis (NSF): the role of tamoxifen. NDT Plus 2010, 3:505.
90. Swaminathan S., Arbiser J.L., Hiatt K.M., et al. Rapid improvement of nephrogenic systemic fibrosis with rapamycin therapy: possible role of phospho-70-ribosomal-S6 kinase. J Am Acad Dermatol 2010, 62:343-345.
91. Cowper SE. Nephrogenic Fibrosing Dermopathy [ICNSFR website] 2001-2010. Available at: Accessed December 12, 2010. http://www.icnsfr.org.
92. Abu Alfa AK. Approach to the use of GBCA in patients with kidney disease. E-Briefing of the Fourth Scientific Symposium on NSF and GBCA. New York, NY: New York. Academy of Sciences; May 14-15, 2010. Available at: Accessed December 26, 2010. http://www.nyas.org/nsf.
93. Saab G, Abu-Alfa AK. Letter to the editor. Radiology. 207;244:930-931; author reply 931-932.
94. Swaminathan S., Shah S.V. New insights into nephrogenic systemic fibrosis. J Am Soc Nephrol 2007, 18:2636-2643.
95. Food and Drug Administration. Joint Meeting of the Cardiovascular and Renal Drugs and Drug Safety and Risk Management Advisory Committee. Gadolinium-Based Contrast Agents and Nephrogenic Systemic Fibrosis. FDA Briefing Document, Advisory Committee; December 8, 2009. Available at: Accessed November 18, 2009. http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/ucm125999.htm.
96. Chapman A., Grantham J.J., Torres V.E., et al. Absence of nephrogenic systemic fibrosis (NSF) following gadolinium exposure in ADPKD individuals with stable CKD. J Am Soc Nephrol 2007, [Abstract], PUB021.
97. Bryant B.J., Im K., Broome D.R. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI. Clin Radiol 2009, 64:706-713.
98. Abujudeh H.H., Rolls H., Kaewlai R., et al. Retrospective assessment of prevalence of nephrogenic systemic fibrosis (NSF) after implementation of a new guideline for the use of gadobenate dimeglumine as a sole contrast agent for magnetic resonance examination in renally impaired patients. J Magn Reson Imaging 2009, 30:1335-1340.
99. Chrysochou C., Power A., Shurrab A.E., et al. Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging. Clin J Am Soc Nephrol 2010, 5:484-489.
100. Bridges M.D., St Amant B.S., McNeil R.B., et al. High-dose gadodiamide for catheter angiography and CT in patients with varying degrees of renal insufficiency: prevalence of subsequent nephrogenic systemic fibrosis and decline in renal function. Am J Roentgenol 2009, 192:1538-1543.
101. Coresh J., Selvin E., Stevens L.A., et al. Prevalence of chronic kidney disease in the United States. JAMA 2007, 298:2038-2047.
102. Castro A.F., Coresh J. CKD surveillance using laboratory data from the population-based National Health and Nutrition Examination Survey (NHANES). Am J Kidney Dis 2009, 53(3 suppl 3):S46-S55.
103. O'Hare A.M., Bertenthal D., Covinsky K.E., et al. Mortality risk stratification in chronic kidney disease: one size for all ages?. J Am Soc Nephrol 2006, 17:846-853.
104. Cheng S., Abramova L., Saab G., et al. Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents - St. Louis, Missouri, 2002-2006. MMWR 2007, 56:137-141. Available at:. http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5607a1.htm.
105. Mendoza F.A., Artlett C.M., Sandorfi N., et al. Description of 12 cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum 2006, 35:238-249.
106. Murashima M., Drott H.R., Carlow D., et al. Removal of gadolinium by peritoneal dialysis. Clin Nephrol 2008, 69:368-372.
107. George S.J., Webb S.M., Abraham J.L., Cramer S.P. Synchrotron X-ray analyses demonstrate phosphate-bound gadolinium in skin in nephrogenic systemic fibrosis. Br J Dermatol 2010, 163:1077-1081.
108. Swaminathan S., Ahmed I., McCarthy J.T., et al. Nephrogenic fibrosing dermopathy and high-dose erythropoietin therapy. Ann Intern Med 2006, 145:234-235.
109. Pieringer H., Schmekal B., Janko O., Biesenbach G. Treatment with corticosteroids does not seem to benefit nephrogenic systemic fibrosis. Nephrol Dial Transplant 2007, 22:3094.
110. Swaminathan S., Horn T.D., Pellowski D., et al. Nephrogenic systemic fibrosis, gadolinium, and iron mobilization. N Engl J Med 2007, 357:720-722.
111. Vorobiov M., Basok A., Tovbin D., et al. Iron-mobilizing properties of the gadolinium-DTPA complex: clinical and experimental observations. Nephrol Dial Transplant 2003, 18:884-887.
112. Panesar M., Boateng F., Patel S.S., et al. Transmetallation and gadolinium: do low iron stores prevent the development of nephrogenic systemic fibrosis in high-risk end-stage renal disease patients?. Hemodial Int 2010, 14:289-294.
113. Fazeli A., Lio P.A., Liu V. Nephrogenic fibrosing dermopathy: are ACE inhibitors the missing link?. Arch Dermatol 2004, 140:1401.
114. Hutchison A.J., Maes B., Vanwalleghem J., et al. Long-term efficacy and tolerability of lanthanum carbonate: results from a 3-year study. Nephron Clin Pract 2006, 102:c61-c71.
115. De Broe M.E. Can the risk of gadolinium be extrapolated to lanthanum?. Semin Dial 2008, 21:142-144.
116. Kuo P.H., Kanal E., Abu-Alfa A.K., Cowper S.E. Gadolinium-based MR contrast agents and nephrogenic systemic fibrosis. Radiology 2007, 242:647-649.
117. Broome D.R., Cottrell A.C., Kanal E. Response to " Will dialysis prevent the development of nephrogenic systemic fibrosis after gadolinium-based contrast administration?" Am J Roentgenol 2007, 189:W234-W235.
118. Weinreb J.C., Kuo P.H. Nephrogenic systemic fibrosis. Magn Reson Imaging Clin N Am 2009, 17:159-167.
119. Grobner T., Prischl F.C. Gadolinium and nephrogenic systemic fibrosis. Kidney Int 2007, 72:260-264.
120. Saab G., Whaley-Connell A.T., McCullough P.A., Bakris G.L. CKD awareness in the United States: the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2008, 52:382-383.
121. Coresh J., Byrd-Holt D., Astor B.C., et al. Chronic kidney disease awareness, prevalence, and trends among U.S. adults, 1999 to 2000. J Am Soc Nephrol 2005, 16:180-188.
122. Patel J., Weinreb J., Abu Alfa A.K. Poster presented at the American Society of Nephrology Meeting Oct 31, 2009, Screening for Chronic Kidney Disease at the Point-of-Care Prior to GBCA Administration, American Society of Nephrology, San Diego, CA, Abstract SA-PO2277.
123. Weinreb J.C., Abu-Alfa A.K. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: why did it happen and what have we learned?. J Magn Reson Imaging 2009, 30:1236-1239.
124. Weinreb J.C. Impact on hospital policy: yale experience. J Am Coll Radiol 2008, 5:53-56.
125. Poggio E.D., Nef P.C., Wang X., et al. Performance of the Cockcroft-Gault and modification of diet in renal disease equations in estimating GFR in ill hospitalized patients. Am J Kidney Dis 2005, 46:242-252.
126. Skluzacek P.A., Szewc R.G., Nolan C.R., et al. Prediction of GFR in liver transplant candidates. Am J Kidney Dis 2003, 42:1169-1176.
127. Prince M.R., Zhang H.L., Roditi G.H., Leiner T., Kucharczyk W. Risk factors for NSF: a literature review. J Magn Reson Imaging 2009, 30:1298-1308.
128. Weinreb J.C. Which study when? Is gadolinium-enhanced MR imaging safer than iodine-enhanced CT?. Radiology 2008, 249:3-8.
129. Martin D.R., Semelka R.C., Chapman A., et al. Nephrogenic systemic fibrosis versus contrast-induced nephropathy: risks and benefits of contrast-enhanced MR and CT in renally impaired patients. J Magn Reson Imaging 2009, 30:1350-1356.